Aperiomics
Company

Last deal

$360.K

Amount

Convertible Note

Stage

14.12.2020

Date

6

all rounds

$5.2M

Total amount

General

About Company
Aperiomics is revolutionizing infection testing for improved global health.

Industry

Sector :

Subsector :

founded date

01.10.2013

Number of employees

Company Type

For Profit

Last funding type

Convertible Note

IPO status

Private

Description

The company offers pathogen testing services that use next-generation sequencing and bioinformatics to identify every known bacteria, virus, fungus, and parasite through Deep Shotgun Metagenomic Sequencing. Aperiomics' world-renowned database containing over 37,000 microbes helps doctors and their patients identify the causes of infections that other tests cannot identify, streamlining the path to a positive clinical outcome. The company has been recognized as Life Science Innovator of the Year in 2016 and International Start Up of the Year in 2018.
Contacts